Repeated agmatine treatment attenuates nicotine sensitization in mice: Modulation by α2-adrenoceptors

Behavioural Brain Research

Volumn 213, Issue 2, 2010, Pages 161-174

  Kotagale, Nandkishor Ramdas ^a   Taksande, Brijesh Gulabrao ^a   Gahane, Avinash Yashwant ^a   Ugale, Rajesh Ramesh ^a   Chopde, Chandrabhan Tukaram ^a  

^a India   (India)

Author keywords

2 Adrenoceptors; Agmatine; Locomotor sensitization; Nicotine

Indexed keywords

AGMATINE; ALPHA 2 ADRENERGIC RECEPTOR; AMINOGUANIDINE; CLONIDINE; IDAZOXAN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINE; NITRIC OXIDE SYNTHASE; YOHIMBINE; ARCAINE; ARGININE; BIGUANIDE DERIVATIVE; EFLORNITHINE; ENZYME INHIBITOR; GUANIDINE DERIVATIVE;

ANALYSIS OF VARIANCE; ARTICLE; BRAIN FUNCTION; CONTROLLED STUDY; DECARBOXYLATION; LOCOMOTION; MALE; MOUSE; NEUROMODULATION; NEUROPHYSIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SENSITIZATION; SIGNAL TRANSDUCTION; SYNAPSE VESICLE; VENTRAL TEGMENTUM; ANIMAL; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG EFFECTS; DRUG INTERACTION; MOTOR ACTIVITY;

AGMATINE; ANIMALS; ARGININE; BIGUANIDES; CLONIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EFLORNITHINE; ENZYME INHIBITORS; GUANIDINES; IDAZOXAN; MALE; MICE; MOTOR ACTIVITY; NICOTINE; RECEPTORS, ADRENERGIC, ALPHA-2; YOHIMBINE;

EID: 77953916968     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.04.049     Document Type: Article

References (80)

1. Alberti K., Wood H., Whalley M. Mechanism of action of the monoguanidine hypoglycemic agents, galegine and agmatine. Eur J Clin Invest 1973, 3:208.
2. Aricioglu-Kartal F., Regunathan S. Effect of chronic morphine treatment on the biosynthesis of agmatine in rat brain and other tissues. Life Sci 2002, 71:1695-1701.
3. Aricioglu-Kartal F., Uzbay I.T. Inhibitory effect of agmatine on naloxone precipitated abstinence syndrome in morphine dependent rats. Life Sci 1997, 61:1775-1781.
4. Auguet M., Viossat I., Marin J.G., Chabrier P.E. Selective inhibition of inducible nitric oxide synthase by agmatine. Jpn J Pharmacol 1995, 69:285-287.
5. Bence A.K., Worthen D.R., Stables J.P., Crooks P.A. An in vivo evaluation of the antiseizure activity and acute neurotoxicity of agmatine. Behav Brain Res 2003, 74:771-775.
6. Buchhalter A.R., Fant R.V., Henningfield J.E. Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status. Drugs 2008, 68(8):1067-1088.
7. Celik E., Uzbay I.T., Karakas S. Caffeine and amphetamine produce cross-sensitization to nicotine-induced locomotor activity in mice. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30(1):50-55.
8. Chen S.Q., Zhai H.F., Cui Y.Y., Shi J., Le Foll B., Lu L. Clonidine attenuates morphine withdrawal and subsequent drug sensitization in rhesus monkeys. Acta Pharmacol Sin 2007, 28(4):473-483.
9. Clarke P.B., Fu D.S., Jakubovic A., Fibiger H.C. Evidence that mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in rats. J Pharmacol Exp Ther 1988, 246(2):701-708.
10. Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol 2000, 393:295-314.
11. Erb S., Hitchcott P.K., Rajabi H., Mueller D., Shaham Y., Stewart J. Alpha-2 adrenergic receptor agonists block stress-induced reinstatement of cocaine seeking. Neuropsychopharmacology 2000, 23(2):138-150.
12. Fairbanks C.A., Wilcox G.L. Spinal antinociceptive synergism between morphine and clonidine persists in mice made acutely or chronically tolerant to morphine. J Pharmacol Exp Ther 1999, 288(3):1107-1116.
13. Galea E., Regunathan S., Eliopoulos V., Feinstein D.L., Reis D.J. Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine. Biochem J 1996, 316:247-249.
14. Gourlay S., Forbes A., Marriner T., Kutin J., McNeil J. A placebo-controlled study of three clonidine doses for smoking cessation. Clin Pharmacol Ther 1994, 55(1):64-69.
15. Halaris A., Piletz J. Agmatine: metabolic pathway and spectrum of activity in brain. CNS Drugs 2007, 21(11):885-900.
16. Harris G.C., Hedaya M.A., Pan W.J., Kalivas P. β-Adrenergic antagonism alters the behavioral and neurochemical responses to cocaine. Neuropsychopharmacology 1996, 14(3):195-204.
17. Hernandez S., Schwarcz de Tarlovsky S. Arginine decarboxylase in Trypanosoma cruzi, characteristics and kinetic properties. Cell Mol Biol (Noisy-le-grand) 1999, 45:383-391.
18. Huang M.J., Regunathan S., Botta M., Lee K., McClendonYi G.B., Pedersen M.L., et al. Structure-activity analysis of guanidine group in agmatine for brain agmatinase. Ann N Y Acad Sci 2003, 1009:52-63.
19. Isome M., Lortie M.J., Murakami Y., Parisi E., Matsufuji S., Satriano J. The antiproliferative effects of agmatine correlate with the rate of cellular proliferation. Am J Physiol Cell Physiol 2007, 293(2):C705-711.
20. Jentsch J.D., Sanchez D., Elsworth J.D., Roth R.H. Clonidine and guanfacine attenuate phencyclidine-induced dopamine overflow in rat prefrontal cortex: mediating influence of the alpha-2A adrenoceptor subtype. Brain Res 2008, 1246:41-46.
21. Jiménez-Rivera C.A., Feliu-Mojer M., Vázquez-Torres R. Alpha-noradrenergic receptors modulate the development and expression of cocaine sensitization. Ann N Y Acad Sci 2006, 1074:390-402.
22. Kalivas P.W., Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Rev 1991, 16:223-244.
23. Kalra S.P., Pearson E., Sahu A., Kalra P.S. Agmatine, a novel hypothalamic amine, stimulates pituitary luteinizing hormone release in vivo and hypothalamic luteinizing hormone-releasing hormone release in vitro. Neurosci Lett 1995, 194(3):165-168.
24. 2-adrenergic and non-adrenergic I-receptor binding sites labelled by [3H]rilmenidine. Brain Res 1995, 675:264-278.
25. Lavinsky D., Arteni N.S., Netto C.A. Agmatine induces anxiolysis in the elevated plus maze task in adult rats. Behav Brain Res 2003, 141(1):19-24.
26. Li G., Regunathan S., Barrow C.J., Eshraghi J., Cooper R., Reis D.J. Agmatine: an endogenous clonidine-displacing substance in the brain. Science 1994, 263:966-969.
27. Li J., Li X., Pei G., Qin B.Y. Correlation between inhibitions of morphine withdrawal and nitric-oxide synthase by agmatine. Zhongguo Yao Li Xue Bao 1999, 20(4):375-380.
28. Li Y.F., Gong Z.H., Cao J.B., Wang H.L., Luo Z.P., Li J. Antidepressant-like effect of agmatine and its possible mechanism. Eur J Pharmacol 2003, 469:81-88.
29. Liu P., Bergin D.H. Differential effects of i.c.v. microinfusion of agmatine on spatial working and reference memory in the rat. Neuroscience 2009, 159(3):951-961.
30. Loring R.H. Agmatine acts as an antagonist of neuronal nicotinic receptors. Br J Pharmacol 1990, 99(1):207-211.
31. Lu G., Su R.B., Li J., Qin B.Y. Modulation by α-difluoromethyl-ornithine and aminoguanidine of pain threshold, morphine analgesia and tolerance. Eur J Pharmacol 2003, 478:139-144.
32. McGehee D.S., Role L.W. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu Rev Physiol 1995, 57:521-546.
33. Miller D.K., Wilkins L.H., Bardo M.T., Crooks P.A., Dwoskin L.P. Once weekly administration of nicotine produces long-lasting locomotor sensitization in rats via a nicotinic receptor-mediated mechanism. Psychopharmacology (Berl) 2001, 156(4):469-476.
34. Miller D.K., Harrod S.B., Green T.A., Wong M.Y., Bardo M.T., Dwoskin L.P. Lobeline attenuates locomotor stimulation induced by repeated nicotine administration in rats. Pharmacol Biochem Behav 2003, 74(2):279-286.
35. 2D-adrenoceptor: competitive antagonism and allosteric activation. Br J Pharmacol 2000, 130:1706-1712.
36. Morgan A.D., Campbell U.C., Fons R.D., Carroll M.E. Effects of agmatine on the escalation of intravenous cocaine and fentanyl self-administration in rats. Pharmacol Biochem Behav 2002, 72:873-880.
37. Nicholas A.P., Pieribone T., Hokfelt V.A. Distributions of mRNAs for alpha 2 adrenergic receptor subtypes in rat brain: an in situ hybridization study. J Comp Neurol 1993, 328:575-594.
38. Olmos G., DeGregorio-Rocasolano N., Paz Regalado M., Gasull T., Assumpció Boronat M., Trullas R., et al. Protection by imidazol(ine) drugs and agmatine of glutamate-induced neurotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor. Br J Pharmacol 1999, 127(6):1317-1326.
39. Onal A., Soykan N. Agmatine produces antinociception in tonic pain in mice. Pharmacol Biochem Behav 2001, 69(1-2):93-97.
40. Onal A., Delen Y., Ulker S., Soykan N. Agmatine attenuates neuropathic pain in rats: possible mediation of nitric oxide and noradrenergic activity in the brainstem and cerebellum. Life Sci 2004, 73:413-428.
41. Otake K., Ruggiero D.A., Regunathan S., Wang H., Milner T.A., Reis D.J. Regional localization of agmatine in the rat brain: an immunocytochemical study. Brain Res 1998, 787(1):1-14.
42. Paxinos G., Franklin R.B.J. The mouse brain in stereotaxic coordinates 1997, Academic Press, San Diego.
43. Pineda J., Ruiz-Ortega J.A., Martín-Ruiz R., Ugedo L. Agmatine does not have activity at alpha 2-adrenoceptors which modulate the firing rate of locus coeruleus neurones: an electrophysiological study in rat. Neurosci Lett 1996, 219(2):103-106.
44. Raasch W., Schafer U., Chun J., Dominiak P. Biological significance of agmatine, an endogenous ligand at imidazoline binding sites. Br J Pharmacol 2001, 133:755-780.
45. Regunathan S., Reis D.J. Characterization of arginine decarboxylase in rat brain and liver: distinction from ornithine decarboxylase. J Neurochem 2000, 74(5):2201-2208.
46. Regunathan S. Agmatine: biological role and therapeutic potential in morphine analgesia and dependence. AAPS J 2006, 8(5):E479-E484.
47. Reis D.J., Regunathan S. Agmatine: an endogenous ligand at imidazoline receptors may be a novel neurotransmitter in brain. J Auton Nerv Syst 1998, 72(2-3):80-85.
48. Reis D.J., Regunathan S. Is agmatine a novel neurotransmitter in brain?. Trends Pharmacol Sci 2000, 21:187-193.
49. Roberts J.C., Grocholski B.M., Kitto K.F., Fairbanks C.A. Pharmacodynamic and pharmacokinetic studies of agmatine after spinal administration in the mouse. J Pharmacol Exp Ther 2005, 314:1226-1233.
50. Robinson T.E., Berridge K.C. Addiction. Annu Rev Psychol 2003, 54:25-53.
51. Roerig S.C. Spinal and supraspinal agmatine activate different receptors to enhance spinal morphine antinociception. Ann N Y Acad Sci 2003, 1009:116-126.
52. Ruiz-Durántez E., Ruiz-Ortega J.A., Pineda J., Ugedo L. Effect of agmatine on locus coeruleus neuron activity: possible involvement of nitric oxide. Br J Pharmacol 2002, 135(5):1152-1158.
53. Sahraei H., Aliabadi A.A., Zarrindast M.R., Ghoshooni H., Nasiri A., Barzegari-Sorkheh A.A., et al. Ascorbic acid antagonizes nicotine-induced place preference and behavioral sensitization in mice. Eur J Pharmacol 2007, 560(1):42-48.
54. Satriano J., Schwartz D., Ishizuka S., Lortie M.J., Thomson S.C., Gabbai F., et al. Suppression of inducible nitric oxide generation by agmatine aldehyde: beneficial effects in sepsis. J Cell Physiol 2001, 188(3):313-320.
55. Schoffelmeer A.N.M., De Vries T.J., Wardeh G., van de Ven H.W.M., Vanderschuren L.J.M.J. Psychostimulant-induced behavioral sensitization depends on nicotinic receptor activation. J Neurosci 2002, 22(8):3269-3276.
56. Selamnia M., Mayeur C., Robert V., Blachicr F. α-Difluoromethylornithine (DFMO) as a potent arginase activity inhibitor in human colon carcinoma cells. Biochem Pharmacol 1998, 55:1241-1245.
57. Shim I., Kim H.T., Kim Y.H., Chun B.G., Hahm D.H., Lee E.H., et al. Role of nitric oxide inhibitors and NMDA receptor antagonist in nicotine-induced behavioural sensitization in the rats. Eur J Pharmacol 2002, 443:119-124.
58. Slotkin T.A., Seidler F.J., Trepanier P.A., Whitmore W.L., Lerea L., Barnes G.A., et al. Ornithine decarboxylase and polyamines in tissues of the neonatal rat: effects of alpha-difluoromethylornithine, a specific, irreversible inhibitor of ornithine decarboxylase. J Pharmacol Exp Ther 1982, 222:741-745.
59. Su R.B., Li J., Gao K., Pei G., Qin B.Y. Influence of idazoxan on analgesia, tolerance, and physical dependence of morphine in mice and rats in vivo. Acta Pharmacol Sin 2000, 21(11):1011-1015.
60. Su R.B., Li J., Qin B.Y. A biphasic opioid function modulator: agmatine. Acta Pharmacol Sin 2003, 24:631-636.
61. Su R.B., Wang W.P., Lu X.Q., Wu N., Liu Z.M., Li J. Agmatine blocks acquisition and re-acquisition of intravenous morphine self-administration in rats. Pharmacol Biochem Behav 2009, 92(4):676-682.
62. Tabor C.W., Tabor H. Polyamines. Ann Rev Biochem 1984, 53:749-790.
63. Tahsili-Fahadan P., Firouz-Abadi N.Y., Khoshnoodi M.A., Langroudi R.M., Tahaei S.A., Ghahremani M.H., et al. Agmatine potentiates morphine-induced conditioned place preference in mice: modulation by alpha(2)-adrenoceptors. Neuropsychopharmacol 2006, 31:1722-1732.
64. Taksande B.G., Kotagale N.R., Tripathi S.J., Ugale R.R., Chopde C.T. Antidepressants like effect of selective serotonin reuptake inhibitors involve modulation of imidazoline receptors by agmatine. Neuropharmacology 2009, 57(4):415-424.
65. Tapper A.R., McKinney S.L., Nashmi R., Schwarz J., Deshpande P., Labarca C., et al. Nicotine activation of α4 receptors: sufficient for reward, tolerance, and sensitization. Science 2004, 306:1029-1032.
66. Ulusu U., Uzbay I.T., Kayir H., Alici T., Karakas S. Evidence for the role of nitric oxide in nicotine-induced locomotor sensitization in mice. Psychopharmacology (Berl) 2005, 178(4):500-504.
67. Uzbay I.T., Yeşilyurt O., Celik T., Ergün H., Işimer A. Effects of agmatine on ethanol withdrawal syndrome in rats. Behav Brain Res 2000, 107(1-2):153-159.
68. Vanderschuren L.J., Beemster P., Schoffelmeer A.N. On the role of noradrenaline in psychostimulant-induced psychomotor activity and sensitization. Psychopharmacology (Berl) 2003, 169(2):176-185.
69. Vezina P., McGehee D.S., Green W.N. Exposure to nicotine and sensitization of nicotine-induced behaviors. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31(8):1625-1638.
70. Villégier A.S., Drouin C., Bizot J.C., Marien M., Glowinski J., Colpaërt F., et al. Stimulation of postsynaptic alpha1b- and alpha2-adrenergic receptors amplifies dopamine-mediated locomotor activity in both rats and mice. Synapse 2003, 50(4):277-284.
71. Wei X.L., Su R.B., Wu N., Lu X.Q., Zheng J.Q., Li J. Agmatine inhibits morphine-induced locomotion sensitization and morphine-induced changes in striatal dopamine and metabolites in rats. Eur Neuropsychopharmacol 2007, 17:790-799.
72. Weng X.C., Gai X.D., Zheng J.Q., Li J. Agmatine blocked voltage-gated calcium channel in cultured rat hippocampal neurons. Acta Pharmacol Sin 2003, 24(8):746-750.
73. Yamanaka K., Oshita M., Muramatsu I. Alteration of alpha and muscarinic receptors in rat brain and heart following chronic nicotine treatment. Brain Res 1985, 348(2):241-248.
74. Yang X.C., Reis D.J. Agmatine selectively blocks the N-methyl-d-aspartate subclass of glutamate receptor channels in rat hippocampal neurons. J Pharmacol Exp Ther 1999, 288:544-549.
75. Yesilyurt O., Uzbay I.T. Agmatine potentiates the analgesic effect of morphine by an alpha(2)-adrenoceptor-mediated mechanism in mice. Neuropsychopharmacology 2001, 25:98-103.
76. Zaniewska M., McCreary A.C., Sezer G., Przegalinski E., Filip M. Effects of agmatine on nicotine-evoked behavioral responses in rats. Pharmacol Reports 2008, 60:645-654.
77. Zeidan M.P., Zomkowski A.D.E., Rosa A.O., Rodrigues A.L.S., Gabilan N.H. Evidence for imidazoline receptors involvement in the agmatine antidepressant-like effect in the forced swimming test. Eur J Pharmacol 2007, 565:125-131.
78. Zheng J.Q., Weng X.C., Gai X.D., Li J., Xiao W.B. Mechanism underlying blockade of voltage-gated calcium channels by agmatine in cultured rat hippocampal neurons. Acta Pharmacol Sin 2004, 25:281-285.
79. Zislis G., Desai T.V., Prado M., Shah H.P., Bruijnzeel A.W. Effects of the CRF receptor antagonist D-Phe CRF(12-41) and the alpha2-adrenergic receptor agonist clonidine on stress-induced reinstatement of nicotine-seeking behavior in rats. Neuropharmacology 2007, 53(8):958-966.
80. Zomkowski A.D., Hammes L., Lin J., Calixto J.B., Santos A.R., Rodrigues A.L. Agmatine produces antidepressant-like effects in two models of depression in mice. Neuroreport 2002, 13:387-391.